WO2002006821A3 - Antimicrobial agent - Google Patents

Antimicrobial agent Download PDF

Info

Publication number
WO2002006821A3
WO2002006821A3 PCT/EP2001/008208 EP0108208W WO0206821A3 WO 2002006821 A3 WO2002006821 A3 WO 2002006821A3 EP 0108208 W EP0108208 W EP 0108208W WO 0206821 A3 WO0206821 A3 WO 0206821A3
Authority
WO
WIPO (PCT)
Prior art keywords
component
bacteria
proteinase
test agent
microbial activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/008208
Other languages
French (fr)
Other versions
WO2002006821A2 (en
Inventor
Lars Bjorck
Inga-Maria Frick
Artur Schmidtchen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Medical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical AB filed Critical Hansa Medical AB
Priority to CA002418214A priority Critical patent/CA2418214A1/en
Priority to EP01967187A priority patent/EP1301797A2/en
Priority to US10/333,319 priority patent/US7335355B2/en
Priority to JP2002512679A priority patent/JP2004504603A/en
Priority to AU2001287628A priority patent/AU2001287628A1/en
Publication of WO2002006821A2 publication Critical patent/WO2002006821A2/en
Publication of WO2002006821A3 publication Critical patent/WO2002006821A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method of identifying an agent that enhances the anti-microbial activity of cationic anti-microbial peptides by blocking the inhibitory effects of the proteinase/glycosaminoglycan pathway, which method comprises: (i) providing, as a first component, a cationic anti-microbial peptide; (ii) providing, as a second component, bacteria; (iii) providing, as a third component, part of all of the components of a proteinase/glycosaminoglycan pathway such that the third component reduces the antimicrobial effect of the first component, for example, a glycosaminoglycan or bacteria or bacteria and a proteoglycan or a bacterial proteinase or a bacterial proteinase and a proteoglycan; (iv) contacting the first, second and third components with a test agent under conditions that would permit the killing of the bacteria by the antimicrobial agent in the absence of the third component, and that would permit the inhibition of the anti-microbial activity of the first component by the third component in the absence of the test agent; (v) monitoring the survival of the bacterial culture thereby determining whether the test agent is capable of enhancing anti-microbial activity wherein a test agent capable of enhancing anti-microbial activity promotes killing of the bacterial culture. Agents identified by such a method are useful in the therapy of acute and chronic infections, particularly in the treatment of ulcers and in the promotion of wound healing.
PCT/EP2001/008208 2000-07-17 2001-07-17 Antimicrobial agent Ceased WO2002006821A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002418214A CA2418214A1 (en) 2000-07-17 2001-07-17 Antimicrobial agent
EP01967187A EP1301797A2 (en) 2000-07-17 2001-07-17 Antimicrobial agent
US10/333,319 US7335355B2 (en) 2000-07-17 2001-07-17 Antimicrobial agent
JP2002512679A JP2004504603A (en) 2000-07-17 2001-07-17 Antimicrobial agent
AU2001287628A AU2001287628A1 (en) 2000-07-17 2001-07-17 Antimicrobial agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00306074 2000-07-17
EP00306074.6 2000-07-17

Publications (2)

Publication Number Publication Date
WO2002006821A2 WO2002006821A2 (en) 2002-01-24
WO2002006821A3 true WO2002006821A3 (en) 2002-06-27

Family

ID=8173129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008208 Ceased WO2002006821A2 (en) 2000-07-17 2001-07-17 Antimicrobial agent

Country Status (7)

Country Link
US (1) US7335355B2 (en)
EP (1) EP1301797A2 (en)
JP (1) JP2004504603A (en)
AU (1) AU2001287628A1 (en)
CA (1) CA2418214A1 (en)
WO (1) WO2002006821A2 (en)
ZA (1) ZA200300013B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223655D0 (en) * 2002-10-10 2002-11-20 Mabtech Ab Method of diagnosis
SE0300207D0 (en) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
EP1587950A2 (en) 2003-01-31 2005-10-26 Ethicon, Inc. Cationic anti-microbial peptides and methods of use thereof
ATE432358T1 (en) * 2003-11-03 2009-06-15 Ethicon Inc COLORIMETRIC SUBSTRATES, COLORIMETRIC SENSORS AND METHODS OF USE
EP3144324A1 (en) 2006-06-02 2017-03-22 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
US20080248508A1 (en) * 2006-08-17 2008-10-09 Shenda Baker Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials
AU2008310076A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag CGRP as a therapeutic agent
CA2817373A1 (en) * 2010-11-10 2012-05-18 The University Of Western Ontario Methods and compositions comprising cyclic analogues of histatin 5 for treating wounds
DE102011077052A1 (en) 2011-06-07 2012-12-13 Beiersdorf Ag Use of epsilon-poly-L-lysine to increase the bioavailability of antimicrobial peptides in human skin.
JP6334265B2 (en) * 2014-05-29 2018-05-30 花王株式会社 Screening method for antibacterial substances

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089939A1 (en) * 1982-03-22 1983-09-28 BioCarp AB Compositions for therapeutic or diagnostic use containing oligosaccharides
EP0356060A2 (en) * 1988-08-18 1990-02-28 Minnesota Mining And Manufacturing Company Wound filling compositions
WO1994003184A1 (en) * 1992-07-31 1994-02-17 Neose Pharmaceuticals, Inc. Compositions for treating and inhibiting gastric and duodenal ulcers
US5968525A (en) * 1992-02-27 1999-10-19 Ambico, Inc. Inactivated Mycolplasma hyopneumoniae and uses therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US5194585A (en) * 1989-04-25 1993-03-16 Igen, Inc. Inhibitors of catalytic antibodies
JP3186607B2 (en) * 1996-11-08 2001-07-11 株式会社村田製作所 Distributed constant line type filter
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089939A1 (en) * 1982-03-22 1983-09-28 BioCarp AB Compositions for therapeutic or diagnostic use containing oligosaccharides
EP0356060A2 (en) * 1988-08-18 1990-02-28 Minnesota Mining And Manufacturing Company Wound filling compositions
US5968525A (en) * 1992-02-27 1999-10-19 Ambico, Inc. Inactivated Mycolplasma hyopneumoniae and uses therefor
WO1994003184A1 (en) * 1992-07-31 1994-02-17 Neose Pharmaceuticals, Inc. Compositions for treating and inhibiting gastric and duodenal ulcers

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ADAMS PHILLIP ET AL: "Defining protease specificity with proteomics: A protease with a dibasic amino acid recognition motif is regulated by a two-component signal transduction system in Salmonella.", ELECTROPHORESIS, vol. 20, no. 11, August 1999 (1999-08-01), pages 2241 - 2247, XP001064681, ISSN: 0173-0835 *
ASPEDON A ET AL: "Involvement of a protease in antimicrobial peptide resistance in Pseudomonas aeruginosa.", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR, vol. 99, 1999, 99th General Meeting of the American Society for Microbiology;Chicago, Illinois, USA; May 30-June 3, 1999, 1999, pages 14, XP001064655, ISSN: 1060-2011 *
BROWN S I ET AL: "THE CORNEA DESTROYING ENZYME OF PSEUDOMONAS-AERUGINOSA", INVESTIGATIVE OPHTHALMOLOGY, vol. 13, no. 3, 1974, pages 174 - 180, XP001064698, ISSN: 0020-9988 *
KESSLER E ET AL: "PSEUDOMONAS PROTEASE PURIFICATION PARTIAL CHARACTERIZATION AND ITS EFFECT ON COLLAGEN PROTEO GLYCAN AND RABBIT CORNEAS", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 16, no. 6, 1977, EN, pages 488 - 497, XP001064692, ISSN: 0146-0404 *
LEHRER R I ET AL: "Antimicrobial peptides in mammalian and insect host defence", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 11, no. 1, 1 February 1999 (1999-02-01), pages 23 - 27, XP004257652, ISSN: 0952-7915 *
NOCK S ET AL: "REVERSIBLE, SITE-SPECIFIC IMMOBILIZATION OF POLYARGININE-TAGGED FUSION PROTEINS ON MICA SURFACES", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 414, September 1997 (1997-09-01), pages 233 - 238, XP002915201, ISSN: 0014-5793 *
SCHMIDTCHEN ARTUR ET AL: "Dermatan sulphate is released by proteinases of common pathogenic bacteria and inactivates antibacterial alpha-defensin.", MOLECULAR MICROBIOLOGY, vol. 39, no. 3, February 2001 (2001-02-01), pages 708 - 713, XP002194955, ISSN: 0950-382X *
See also references of EP1301797A2 *

Also Published As

Publication number Publication date
WO2002006821A2 (en) 2002-01-24
CA2418214A1 (en) 2002-01-24
US7335355B2 (en) 2008-02-26
EP1301797A2 (en) 2003-04-16
AU2001287628A1 (en) 2002-01-30
ZA200300013B (en) 2004-03-24
US20040028672A1 (en) 2004-02-12
JP2004504603A (en) 2004-02-12

Similar Documents

Publication Publication Date Title
Azevedo et al. Hard-to-heal wounds, biofilm and wound healing: an intricate interrelationship
WO2001064132A3 (en) Wound dressings with protease-lowering activity
ATE219684T1 (en) ANTI-GRAM POSITIVE BACTERIAL METHODS AND AGENT
EP1283050A3 (en) Improved therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
DK0759774T3 (en) Method of treating gram-negative bacterial infection by administration of bactericidal / permeability-increasing (BPI) protein product and antibiotic
CA2266811A1 (en) Method and composition for wound treatment
WO2002006821A3 (en) Antimicrobial agent
AU6339599A (en) Quinoline derivatives and their use as antibacterial agents
MXPA05006359A (en) Disease treatment via antimicrobial peptide inhibitors.
DE69635671D1 (en) USE OF ROXITHROMYCIN FOR THE MANUFACTURE OF A MEDICAMENT FOR IMPROVING THE BIOLOGICAL AND ANTIVIRAL ACTIVITY OF PROTEASE INHIBITORS
BRPI9510423B8 (en) low rigidity multilamellar liposomal formulation and anti-infectious formulation
DE60331849D1 (en) ANTIBACTERIAL ACTIVE SUBSTANCES
GB0404374D0 (en) Treatment of bacterial infections
DE69914911D1 (en) PHARMACEUTICAL PREPARATIONS FOR CONTROLLING OR PROPHYLAXIS OF SURFACES INFECTED BY MICRO-ORGANISMS
Hirsch et al. Antimicrobial activity of clinically used antiseptics and wound irrigating agents in combination with wound dressings
Fabry et al. Activity of the antiseptic polyhexanide against meticillin-susceptible and meticillin-resistant Staphylococcus aureus
WO1997030714A3 (en) Topical pharmaceutical composition containing heparin
DE60131085D1 (en) ANTIMICROBIAL SULFONAMIDE DERIVATIVES OF LIPOPEPTIDEANTIBIOTICS
NZ509051A (en) Chemotaxis-inhibiting protein of staphylococcus (CHIPS) and its use
ATE260097T1 (en) HOPS ACIDS TO INHIBIT STAPHYLOCOCCUS AUREUS
AU5128000A (en) Collagen-binding proteins from enterococcal bacteria
DE69906701D1 (en) TOPICAL USE OF LOPERAMIDE FOR TREATING MICROBIAL INFECTIONS
AU9067198A (en) Proton pump inhibitor in therapeutic combination with antibacterial substances
AU2002360218A1 (en) A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A Beta -LACTAM ANTIBIOTIC
EP0974360A3 (en) Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2003/00013

Country of ref document: ZA

Ref document number: 200300013

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001287628

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2418214

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001967187

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001967187

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10333319

Country of ref document: US